

<b>Reference:</b>	FOI.7013.21
<b>Subject:</b>	Use of anti-VEGF treatments for eye conditions
<b>Date of Request:</b>	27 September 2021

**Requested:**

1. For the 4-month period from May to August 2021, how many patients has your trust treated with the following anti-VEGF treatments:
  - Aflibercept
  - Bevacizumab
  - Brolucizumab
  - Dexamethasone
  - Fluocinolone acetonide
  - Ranibizumab
  
2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.
  - Aflibercept
  - Bevacizumab
  - Brolucizumab
  - Dexamethasone
  - Fluocinolone acetonide
  - Ranibizumab
  
3. Within your trust, how many intra-vitreous injections/implants of each following treatments have been used (for any eye condition) in the four-month period from May to August 2021:
  - Aflibercept
  - Bevacizumab
  - Brolucizumab
  - Dexamethasone
  - Ranibizumab
  
4. If your trust is able to identify intra-vitreous injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from May to August 2021 for Wet Age Related Macular Degeneration (wAMD) ONLY
  - Aflibercept
  - Bevacizumab
  - Brolucizumab
  - Dexamethasone
  - Ranibizumab

**Response:**

1. Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients that received the anti-VEGF treatments listed, during the period May to August 2021.

Treatment	Number of patients
Aflibercept	839
Bevacizumab	0
Brolucizumab	*
Dexamethasone	9
Fluocinolone acetonide	0
Ranibizumab	996

2. The UHB provides, within the table overleaf, the number of first time patients that received the anti-VEGF treatments listed, during the period May to August 2021.

Treatment	Number of patients
Aflibercept	99
Bevacizumab	0
Brolucizumab	0
Dexamethasone	0
Fluocinolone acetonide	0
Ranibizumab	87

3. The UHB provides, within the table below, the number of intra-vitreous injections/implants for each of the listed treatments, during the period May to August 2021.

Treatment	Number used
Aflibercept	1,826
Bevacizumab	0
Brolucizumab	*
Dexamethasone	25
Ranibizumab	1,992

4. The UHB provides, within the table below, the number of intra-vitreous injections/implants used to treat Wet Age Related Macular Degeneration (WAMD), during the period May to August 2021.

Treatment	WAMD
Aflibercept	1,212
Bevacizumab	0
Brolucizumab	*
Dexamethasone	0
Ranibizumab	1,225

Where the figures in the tables have been replaced with an asterisk (\*), the UHB is unable to provide you with the exact numbers, due to the low number of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018/General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 define personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.